All ACR and ARP members are invited to apply to join colleagues and patients in Washington, D.C., on Sept. 19–20 for advocacy training and meetings with legislators to advocate on priority issues that affect rheumatology providers and patients.
Keep ACR’s Advocacy Voice Strong with the American Medical Association
As the result of years of coalition work with partners at the AMA, the ACR recently celebrated a major advocacy win when the FTC announced an investigation of PBM business practices. Join or renew your AMA membership before Sept. 1 so the ACR can keep delegate seats to drive action within the AMA.
The ACR Responds to Reports of Treatment Denials in Wake of Dobbs v. Jackson Women’s Health Organization
The ACR is aware of the emerging concerns surrounding access to needed treatments, such as methotrexate, after the recent decision in Dobbs v. Jackson Women’s Health Organization. We are following this issue closely to determine if rheumatologists and rheumatology providers and patients are experiencing any widespread difficulty accessing methotrexate, and if any initial disruptions are…
OA Prevalence Primarily on the Rise
Background & Objectives Worldwide, osteoarthritis (OA) is a highly prevalent, chronic joint disease that causes pain, disability and loss of function. Global trends demonstrated an increase of more than 100% in years lived with disability due to OA from 1990 to 2019. However, no nonsurgical intervention exists to prevent, halt or even delay OA progression….
ACR-FDA Summit Focuses on Study Design, Safety Considerations
Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.
American Medical Association House of Delegates Meets In-Person; ACR Successfully Advances New Policies
The ACR’s resolution addressing inappropriate Medicare Administrative Contractor policy processes was adopted, and two co-led resolutions on ARPA-H funding and saline shortages also passed the policy-making body.
PsA Trial Design Can Improve Patient Safety, Outcomes
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
Some Cannabis Products May Ease Chronic Pain, But Side Effects Are a Concern
NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…
Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising
In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.
Gene Profiling May Predict Treatment Response in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say.1 “We believe this study is a paradigm shift in precision medicine in RA,” Dr. Costantino…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 309
- Next Page »